Best Breast Cancer Hospital in Hyderabad - 11 Centres, NCCN Protocols, NABH-Accredited Partners

Breast cancer surgery should be performed by a surgical oncologist with specific breast cancer expertise — comfortable with both breast-conserving surgery (lumpectomy) and mastectomy, and ideally with oncoplastic techniques that combine cancer surgery with cosmetic preservation. Around the surgeon, the team needs a medical oncologist experienced across all subtype-specific therapies (hormone therapy, HER2-targeted, chemotherapy, immunotherapy), a radiation oncologist with breast experience, a breast radiologist for mammography/ultrasound/MRI interpretation, a breast pathologist for receptor testing, a plastic surgeon for reconstruction, and a genetic counsellor for BRCA cases. Ask for named team credentials in writing. Walk away if the surgery is being recommended by a general surgeon without specific breast cancer training.

A breast cancer tumour board reviews the imaging, biopsy with receptor results (ER, PR, HER2, Ki-67), staging studies, and patient factors. Treatment is matched to the subtype: hormone-positive disease gets hormone therapy as the backbone, sometimes with chemotherapy and CDK4/6 inhibitors for higher-risk cases; HER2-positive disease gets trastuzumab-based therapy; triple-negative disease gets chemotherapy with immunotherapy for some. The choice between breast-conserving surgery and mastectomy is patient-facing and decided in this conversation. Walk away if treatment is being recommended before complete receptor testing results are available.

Breast cancer surgery has a strong volume-outcome relationship. Centres performing more breast cancer operations have better cosmetic outcomes after breast-conserving surgery, better margin clearance rates, lower complication rates, and more experience with oncoplastic techniques. Ask: "How many breast cancer operations did your team perform last year? What proportion were breast-conserving versus mastectomy? Re-excision rate for positive margins?" Walk away if the surgical team cannot quote specific annual numbers.

Every breast cancer biopsy must be tested for ER, PR, HER2, and Ki-67 — these determine which subtype you have and which treatment will work. For HER2 that's borderline on immunohistochemistry, FISH confirmation is needed. For triple-negative cases, PD-L1 testing is added for immunotherapy decisions. For patients with strong family history, diagnosis under age 50, bilateral disease, or triple-negative cancer at any age, BRCA1/BRCA2 genetic testing should be discussed. Walk away if treatment is starting before complete receptor results are available.

Sentinel lymph node biopsy — sampling only the first one or two lymph nodes that drain the breast — has replaced full axillary dissection as the standard approach for clinically node-negative breast cancer. If the sentinel nodes are clear, the rest don't need to come out. This dramatically reduces the risk of lymphedema (chronic arm swelling that is often lifelong). Hospitals still doing full axillary dissection by default for early-stage cancer are using outdated practice. Walk away if the surgical team does not offer sentinel lymph node biopsy as the standard approach.

Breast cancer surgery requires specialised infrastructure: a dedicated operating theatre with imaging-guided localisation for non-palpable tumours, capability for frozen-section margin assessment during surgery, sentinel lymph node mapping equipment (dye or radioisotope), and a team comfortable with both breast-conserving and mastectomy operations. Reconstruction (implant-based or autologous tissue flap) needs trained plastic surgeons. Radiation requires linear accelerators with image-guidance for accurate targeting that protects the heart and lung. NABH-accredited partners signal audited safety. Walk away if the hospital cannot name partner facilities for surgery, reconstruction, and radiation.

Breast cancer treatment costs vary widely. Surgery and standard chemotherapy are predictable. Trastuzumab — once prohibitively expensive — is now widely affordable thanks to biosimilars in India. Hormone therapy with generic aromatase inhibitors and tamoxifen is very affordable long-term. But CDK4/6 inhibitors, PARP inhibitors, and immunotherapy add substantial ongoing cost. A hospital not empanelled for your insurance or ArogyaSri at the centre where treatment happens can derail planning. Walk away if cost estimates change after admission — a serious hospital writes them down beforehand.

Genetic counselling and BRCA testing is important for women diagnosed under age 50, with triple-negative cancer, bilateral disease, or strong family history — implications matter for the patient (different surveillance, PARP inhibitor eligibility) and for daughters and sisters. Lymphedema management (preventing and treating chronic arm swelling after lymph node surgery or radiation) is a distinctive survivorship need — early physiotherapy intervention matters. Surveillance includes regular clinical examination, annual mammography, and hormone therapy monitoring for 5–10 years. Walk away if the hospital does not name genetic counselling and lymphedema management as part of the standard pathway.